Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.

For instance, over a mean follow-up of 2.6 years, CV events occurred in 5.2 % of patients with biopsy-proven NASH vs 2.7 % of patients with NAFLD but without NASH in a Spanish registry study, but the difference did not reach statistical significance [ 9 ].

also in 111,027 other papers